You are here

  • Home
  • Archive
  • Volume 70, Issue 8
  • Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials

Authors

  1. Correspondence to Dr A Mahr, Department of Internal Medicine, Hospital Saint-Louis, 1 avenue Claude-Vellefaux, 75475 Paris Cedex 10, France; alfred.mahr{at}sls.aphp.fr
View Full Text

Citation

Heijl C, Harper L, Flossmann O, et al
Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials
Annals of the Rheumatic Diseases 2011;70:1415-1421.

Publication history

  • Accepted March 21, 2011
  • First published May 25, 2011.
Online issue publication 
October 25, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions